RECEIVED

MAY 2 0 2003

TECH CENTER 1600/2900

Certificate of Express or First-Class Mailing

I hereby certify that I have deposited this correspondence with the US-Postal Service as first-class or, if a mailing-label number is given below, as express mail addressed to Comm. of Patents, Washington, DC 20231 on the below-given date.

MAY 16 2003

EV330901806

Inventor

IN THE

Bernd KIKMANNS et al

PATENT AND TRADEMARK OFFICE

Patent App.

09/529,043 (US Nat'l phase of PCT/EP98/06210)

Filed

3 April 2000

Conf. No. 6651

For

2143

NUCLEIC ACID ENCODING PYRUVATE CARBOXYLASE FROM

CORYNEFORM GLUTAMICUM

Art Unit

1652

Examiner Steadman, D

Hon. Commissioner of Patents Box 1450 Alexandria, VA 22313-1450

COMMUNICATION

This communication is to confirm a telephone conversation between Examiner Steadman and the undersigned. The telephone conversation took place on 14 May 2003. Examiner Steadman indicated that there would be no need for EIKMANNS et al to file an amendment in the instant patent application which would include at least one of the claims to the polypeptide covered in U.S. Patent 6,403,351 to be sure that the polypeptide wold be included in the same interference as the plynucleotide covered in U.S. Patent 6,171,833. Examiner Steadman indicated that one interference could support counts to both the new polynucleotide and the new polypeptide expressed by the polynucleotide.

Pat. App. 09/529,043

Atty s 21437

Thus there would be no need for EIKMANNS et al to file an amendment in the present application adding claims to the polypeptides claimed in U.S. Patent 6,403,351.

Respectfully submitted, The Firm of Karl F. Ross P.C.

> by: Jonathan Myers, 26,963 Attorney for Applicant

15 May 2003 5676 Riverdale Avenue Box 900

Bronx, NY 10471-0900 Cust. No.: 535

Tel: (718) 884-6600 Fax: (718) 601-1099

ge/